URCH reports in their newly available Cancer Market Trends 2008 – 2012 that Roche is expected to overtake Amgen as the top seller of oncology products. Only Genentech and Merck are expected to post double digit growth, causing a shift in balance for former leaders anofi-Aventis, AstraZeneca and Johnson & Johnson.
Other key findings from this report:
- The global cancer market grew to US$66.2 billion in 2007, a year-on-year increase of 13.3%.
- This market growth in 2007 was primarily driven by growth of 44.0% in innovatives sales.
- There were a total of 21 different cancer therapies generating global sales in excess of US$1 billion in 2007.
- The leading company by cancer sales in 2007 was Amgen, with sales of US$11.1 billion.
- The global cancer market is forecast to expand to US$103.9 billion in 2012, equivalent to a CAGR of 9.4% over the next 5 years.
Indicated Actions:
- Health care advertising and public relations firms should gear up accordingly. If you don’t have relationships in place, now is the time to get going.
- Learn more about “personalized medicine” - diagnosis and treatment based on sequencing DNA. Companies like 23 and Me are offering genomic sequencing for individuals for $399. Individuals buying these services are the new influencers.
- Be grateful that a new era of cancer treatment is upon us, offering new hope for terrifying diagnoses.
By way of FierceBiotech and SeekingAlpha. See also New York Times article “My Genome, My Self.“
You might also be interested in these related posts:
- Online Healthcare Records Challenge Privacy ConcernsWe all know that Google reads our email. Those contextual ads in Gmail are the...